Dynogen’s DDP733 Enters Phase IIb Trials

Dynogen Pharmaceuticals has dosed the first patients in the Phase IIb trial of DDP733 as a treatment for irritable bowel syndrome with constipation (IBS-c).

The randomized, double-blind, placebo-controlled DDP733 (pumosetrag) trial will enroll female patients with IBS-c at multiple centers in the U.S. and Canada, the company said.

In February, Dynogen announced positive results from its Phase IIa study of DDP733 in IBS-c with a 54 percent response rate in patients receiving the 1.4-mg dose of the drug compared with a 15 percent response rate for patients receiving placebo.